Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Phase 1 Study to Assess the Pharmacokinetics and Safety of HALAVEN in Subjects With Cancer Who Also Have Impaired Renal Function

NCT01418677 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT01418677
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01418677 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Phase 1 Study to Assess the Pharmacokinetics and Safety of HALAVEN in Subjects With Cancer Who Also Have Impaired Renal Function
Lead sponsor
Eisai Inc.
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2011
Completion date
May 31, 2015
Enrollment
19 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

unspecified adult solid tumor, protocol specific